– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical ...

Italy: Patients with prostate cancer receiving maximal androgen blockade therapy face a significantly higher risk of bone ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

A real-world data claims-based review of CAR-T procedures, time to adverse events, patient characteristics and social factors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

For each 10-year increase in patient age, the relative overall survival benefit of an androgen receptor pathway inhibitor declined by 11%. Adding an androgen receptor pathway inhibitor (ARPI) to ...

Presentation title: A Clinical Trial Combining a Tumor Targeting Immunocytokine (PDS01ADC) and Enzalutamide without Testosterone Lowering Therapy in Biochemically Recurrent Prostate Cancer Presenter: ...